News -

The latest issue of the journal Gen highlights iLite™ reporter gene assays

An article on the characteristics and utility of Euro Diagnostica´s cell based assays, iLite™, was published in the latest issue of the journal Gen (Nov 1, 2015 (Vol. 35, No. 19)).

The article highlights how the iLite™ reporter gene cell lines can quantify the activity of a range of biopharmaceuticals as well as antibody-dependent cytotoxicity. The iLite™ portfolio includes assays for a number of interleukins, interferons, and TNF-α, and new cell lines are in pipeline. “The main advantage for these assays is that these same cell lines can be used in drug discovery, for quantifying drug potency, and to analyze the functional drug levels and antidrug neutralizing antibodies”, says Dr. Michael Tovey, Managing Director of Biomonitor SAS, Euro Diagnostica’s newly established innovation and development centre in Paris.

Read the full article here.

You find more information about the iLite™ technology and product offerings here.

Related links

Topics

  • Medicine, Pharmaceuticals

Categories

  • ilite cell-based assays
  • knowledge

Related media

Media Content Panel
iLite™ Technology 3D picture
License:
© All rights reserved (allow download)
more info...
Download

Related content

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

Discover new iLite™ IL-23 Assay Ready Cells

We are happy to introduce the iLite™ IL-23 Assay Ready Cells offering significant benefits as compared to conventional IL-23 assays. Using the iLite™ IL-23 Assay Ready Cells, a rapid assay for the functional activity of IL-23, without cross-reactivity with IL-12, can easily be set-up. Results are obtained within 6 h.

Announcing the launch of iLite™ VEGF Assay Ready Cells

The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

Enter your email address to follow Euro Diagnostica AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Euro Diagnostica AB.

Okay